Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Metabolic syndrome has been reported to be a risk factor for metachronous colorectal neoplasia (CRN). However, the impact of nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, on the development of metachronous CRN after polypectomy has been rarely examined. We evaluated the association between NAFLD and the development of metachronous CRN after polypectomy. Methods: Asymptomatic subjects who underwent abdominal ultrasonography and endoscopic removal of ≥ 1 adenomas at the index colonoscopy between 2010 and 2014, and had a follow-up surveillance colonoscopy until 2017 were analyzed. Results: Of 6,182 participants, 2,642 (42.7%) had NAFLD at the time of the index colonoscopy. Patients with NAFLD had significantly higher cumulative incidence rates of metachronous overall CRN than those without NAFLD in both men (19.4% vs. 18.2% at 3 years and 49.2% vs. 44.0% at 5 years; p = 0.001) and women (18.7% vs. 10.5% at 3 years and 56.1% vs. 29.8% at 5 years; p < 0.001). Even after adjusting for confounders, NAFLD remained independently associated with an increased risk of metachronous overall CRN in both men (adjusted hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.06 to 1.29) and women (adjusted HR, 1.63; 95% CI, 1.27 to 2.07). Additionally, NAFLD was an independent risk factor for metachronous advanced CRN (ACRN) in women (adjusted HR, 2.61; 95% CI, 1.27 to 5.37). Conclusions: NAFLD is related to an increased risk of metachronous CRN after polypectomy. Especially, women with NAFLD are at an increased risk of developing metachronous ACRN. Our results indicate a possible effect of NAFLD on the pathogenesis of CRN.
Abstract
Background/Aims: Metabolic syndrome has been reported to be a risk factor for metachronous colorectal neoplasia (CRN). However, the impact of nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, on the development of metachronous CRN after polypectomy has been rarely examined. We evaluated the association between NAFLD and the development of metachronous CRN after polypectomy. Methods: Asymptomatic subjects who underwent abdominal ultrasonography and endoscopic removal of ≥ 1 adenomas at the index colonoscopy between 2010 and 2014, and had a follow-up surveillance colonoscopy until 2017 were analyzed. Results: Of 6,182 participants, 2,642 (42.7%) had NAFLD at the time of the index colonoscopy. Patients with NAFLD had significantly higher cumulative incidence rates of metachronous overall CRN than those without NAFLD in both men (19.4% vs. 18.2% at 3 years and 49.2% vs. 44.0% at 5 years; p = 0.001) and women (18.7% vs. 10.5% at 3 years and 56.1% vs. 29.8% at 5 years; p < 0.001). Even after adjusting for confounders, NAFLD remained independently associated with an increased risk of metachronous overall CRN in both men (adjusted hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.06 to 1.29) and women (adjusted HR, 1.63; 95% CI, 1.27 to 2.07). Additionally, NAFLD was an independent risk factor for metachronous advanced CRN (ACRN) in women (adjusted HR, 2.61; 95% CI, 1.27 to 5.37). Conclusions: NAFLD is related to an increased risk of metachronous CRN after polypectomy. Especially, women with NAFLD are at an increased risk of developing metachronous ACRN. Our results indicate a possible effect of NAFLD on the pathogenesis of CRN.
참고문헌 (39)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Otto S. Lin, "Impact of Sigmoidoscopy and Colonoscopy on Colorectal Cancer Incidence and Mortality: An Evidence-Based Review of Published Prospective and Retrospective Studies", Intestinal research, 12(4), pp.268~274 (2014), 대한장연구학회
- Lieberman DA, "Guidelines for colonoscopy surveillance after screening and polypectomy : a consensus update by the US Multi-Society Task Force on Colorectal Cancer", Gastroenterology, 143, pp.844~857 (2012)
- 홍성노, "폴립절제 후 추적대장내시경검사 가이드라인", 대한소화기학회지, 59(2), pp.99~117 (2012), 대한소화기학회
- Cairns SR, "Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups(update from 2002)", Gut, 59, pp.666~689 (2010)
- Kim MC, "Metabolic syndrome is associated with increased risk of recurrent colorectal adenomas in Korean men", Int J Obes(Lond), 36, pp.1007~1011 (2012)
- Kim NH, "Metabolic syndrome is a risk factor for adenoma occurrence at surveillance colonoscopy: a single-center experience in Korea", Medicine (Baltimore), 95, pp.e4454~ (2016)
- Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines : management of nonalcoholic fatty liver disease", Clin Mol Hepatol, 19, pp.325~348 (2013)
- Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
- Sanna C, "Non-alcoholic fatty liver disease and extra-hepatic cancers", Int J Mol Sci, 17, pp.E717~ (2016)
- Lee YI, "Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women : a retrospective cohort study", J Gastroenterol Hepatol, 27, pp.91~95 (2012)
- Stadlmayr A, "Nonalcoholic fatty liver disease : an independent risk factor for colorectal neoplasia", J Intern Med, 270, pp.41~49 (2011)
- Ding W, "Association between nonalcoholic fatty liver disease and colorectal adenoma : a systematic review and meta-analysis", Int J Clin Exp Med, 8, pp.322~333 (2015)
- Shen H, "Association between nonalcoholic fatty liver disease and colorectal adenoma : a systemic review and meta-analysis", J Gastrointest Oncol, 5, pp.440~446 (2014)
- Ze EY, "The Fatty Liver Index : a simple and accurate predictor of colorectal adenoma in an average-risk population", Dis Colon Rectum, 61, pp.36~42 (2018)
- Ahn JS, "Non-alcoholic fatty liver diseases and risk of colorectal neoplasia", Aliment Pharmacol Ther, 45, pp.345~353 (2017)
- Soweid AM, "A randomized single-blind trial of standard diet versus fiber-free diet with polyethylene glycol electrolyte solution for colonoscopy preparation", Endoscopy, 42, pp.633~638 (2010)
- Wen CP, "Are Asians at greater mortality risks for being overweight than Caucasians? : redefining obesity for Asians", Public Health Nutr, 12, pp.497~506 (2009)
- Hamaguchi M, "The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation", Am J Gastroenterol, 102, pp.2708~2715 (2007)
- Chang Y, "Metabolically healthy obesity and the development of nonalcoholic fatty liver disease", Am J Gastroenterol, 111, pp.1133~1140 (2016)
- Viera AJ, "Understanding interobserver agreement : the kappa statistic", Fam Med, 37, pp.360~363 (2005)
- Marchesini G, "Nonalcoholic fatty liver disease : a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
- Williams CD, "Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a prospective study", Gastroenterology, 140, pp.124~131 (2011)
- Targher G, "Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men : role of visceral adipose tissue", Diabet Med, 22, pp.1354~1358 (2005)
- Ahmed RL, "The metabolic syndrome and risk of incident colorectal cancer", Cancer, 107, pp.28~36 (2006)
- Giovannucci E, "Metabolic syndrome, hyperinsulinemia, and colon cancer : a review", Am J Clin Nutr, 86, pp.s836~s842 (2007)
- Sanyal AJ, "Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
- Wong VW, "Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 4, pp.1154~1161 (2006)
- Renehan AG, "Insulin-like growth factor(IGF)-I, IGF binding protein-3, and cancer risk : systematic review and meta-regression analysis", Lancet, 363, pp.1346~1353 (2004)
- Kim S, "Circulating levels of inflammatory cytokines and risk of colorectal adenomas", Cancer Res, 68, pp.323~328 (2008)
- Mutoh M, "Plasminogen activator inhibitor-1(Pai-1)blockers suppress intestinal polyp formation in Min mice", Carcinogenesis, 29, pp.824~829 (2008)
- Yamaji T, "Interaction between adiponectin and leptin influences the risk of colorectal adenoma", Cancer Res, 70, pp.5430~5437 (2010)
- Huang KW, "Patients with n onalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy", Colorectal Dis, 15, pp.830~835 (2013)
- Yang YJ, "Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm : propensity score matching analysis", PLoS One, 12, pp.e0182014~ (2017)
- Mikolasevic I, "Non-alcoholic fatty liver disease and colorectal cancer", Postgrad Med J, 93, pp.153~158 (2017)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease : meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Rex DK, "Colorectal cancer screening : recommendations for physicians and patients from the U. S. Multi-Society Task Force on Colorectal Cancer", Am J Gastroenterol, 112, pp.1016~1030 (2017)
- Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)